Inhibition of α-Amylase and α-Glucosidase by New β-Aminopropionamidoxime Derivatives

L. A. Kayukova, A. B. Uzakova, G. P. Baitursynova, G. T. Dyusembaeva, Z. T. Shul’gau, A. E. Gulyaev, Sh D. Sergazy

Research output: Contribution to journalArticlepeer-review

Abstract

New antidiabetic agents are being sought because of the global problem with diabetes. Amidoxime derivatives are known to have antidiabetic activity. β-Aminopropionamidoxime bases and pharmacologically acceptable salts of O-aroyl-β-(morpholin-1-yl)propionamidoximes and 5-substituted phenyl-3-β-(piperidin-1-yl and morpholin-1-yl)ethyl-1,2,4-oxadiazoles were screened in vitro for antidiabetic activity manifested as inhibition of α-amylase and α-glucosidase. Compounds with pronounced antidiabetic properties were identified. The series of 3,5-disubstituted 1,2,4-oxadiazoles were more active than the series of O-aroyl-β-aminopropionamidoximes. The results could be used for further in vivo screening of the antidiabetic properties of the most promising compounds with a preliminary assessment of their mean toxic doses in animals.

Original languageEnglish
Pages (from-to)129-133
Number of pages5
JournalPharmaceutical Chemistry Journal
Volume53
Issue number2
DOIs
Publication statusPublished - May 5 2019

Keywords

  • bases and pharmacologically acceptable salts of O-aroyl-β-(morpholin-1-yl)propionamidoximes and 5-substituted phenyl-3-β-(piperidin-1-yl and morpholin-1-yl)ethyl-1,2,4-oxadiazoles
  • in vitro antidiabetic screening for inhibition of α-amylase and α-glucosidase

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Inhibition of α-Amylase and α-Glucosidase by New β-Aminopropionamidoxime Derivatives'. Together they form a unique fingerprint.

Cite this